natgillin/translations-raw huggingface dataset:
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropidin. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, propikonazola, kiprokonazola i epoksikonazola.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropidin. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, ipkonazola, protiokonazola, tebukonazola, epoksikonazola, propikonazola i kiprokonazola.
a is independently 0 or 1; 
a je nezavisno 0 ili 1;
b is independently 0 or 1; 
b je nezavisno 0 ili 1;
The compound according to Claim 1 of the Formula II: or pharmaceutically acceptable salts thereof, wherein a is independently 0 or 1; 
Spoj prema zahtjevu 1 koji ima Formulu II: [image] ili njegove farmaceutski prihvatljive soli, gdje a je nezavisno 0 ili 1;
The compound according to Claim 2 of the Formula III: or a pharmaceutically acceptable salt or stereoisomer thereof, wherein a is independently 0 or 1; 
Spoj prema zahtjevu 2 koji ima Formulu III: [image] ili njegova farmaceutski prihvatljiva sol ili stereoizomer, gdje a je nezavisno 0 ili 1;
wherein the term 'aryl' refers to a substituted or unsubstituted aromatic or heteroaromatic, or heterocyclic radical (heteroarylaryl groups are subsumed in this term), and wherein the term aryl also encompasses the benzyl group; 
gdje se termin "aril" odnosi na supstituirani ili nesupstituirani aromatski ili heteroaromatski ili heterociklički radikal (taj termin obuhvaća i heteroarilarilne skupine), te gdje termin aril obuhvaća i benzilnu skupinu;
A pharmaceutical composition comprising a compound according to any one of claims 1 to 2, or a pharmaceutically acceptable salt, enantiomer, racemate, diastereomer, or mixture of diastereomers thereof, and at least one of: a carrier, diluent, and excipient 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentni zahtjeva 1 do 7, ili njegovu farmaceutski prihvatljivu sol, enantiomer, racemat, dijastereomer ili smjesu dijastereomera, kao i najmanje jedno od sljedećeg: podlogu, razrjeđivač i pomoćnu tvar.
A compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt, enantiomer, racemate, diastereomer, or mixture of diastereomers thereof, for use in treating pathological sequelae due to low levels of plasma HDL-cholesterol in a mammal. 
Spoj u skladu s bilo kojim od patentni zahtjeva 1 do 7 ili njegova farmaceutski prihvatljiva sol, enantiomer, racemat, dijastereomer ili smjesa dijastereomera, naznačen time što je namijenjen upotrebi u liječenju patoloških posljedica niskih razina HDL-kolesterola u plazmi kod sisavca.
R9, at each occurrence, is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, hetcroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R9a; 
, svaki put kada je prisutan, je nezavisno izabran između vodika, alkil, alkoksi, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil, gdje alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-5 R9a;
R9, at each occurrence, is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R9a; 
, svaki put kada je prisutan, je nezavisno izabran između vodika, alkil, alkoksi, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil, gdje alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-5 R9a;
is selected from the group consisting of hydrogen, alkyl, haloalkyl, halo and -CN. 
je izabran iz grupe koja obuhvaća vodik, alkil, halogenalkil, halogen i -CN.
The method as defined in claim 1 or 2, wherein in the step of forming the twisted portion, at least a part of an outer periphery of the twisted portion is covered with at least a part of the adhesive applied to the outer periphery of the stuffed casing. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je, u koraku za izradu uvrnutog predjela, najmanje jedan dio vanjskog oboda uvrnutog predjela prekriven s najmanje jednim dijelom ljepljivog materijala koji je nanesen na vanjski obod ovitka s ispunom.
is morpholine, optionally substituted by 1 to 3, same or different substituents R14, or NR12R13; 
je [image] morfolin, po izboru supstituiran s 1 do 3 ista ili različita supstituenta R14 ili NR12R13;
A pharmaceutical composition comprising a compound of any of claims 1 to 6 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak naznačen time da sadržava spoj iz bilo kojeg patentnog zahtjeva od 1. do 6. i farmaceutski prihvatljiv nosač.
A compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein: 
Spoj sa formulom (I): [image] ili njegova farmaceutski prihvatljiva sol, naznačen time da:
The compound of claim 6, wherein the -(C1-C6) alkyl group is a tert -butyl group or an iso -propyl group. 
Spoj prema zahtjevu 6, naznačen time da -(C1-C6) alkilna skupina je fert-butilna skupina ili izo-propilna skupina.
The compound of claim 37, wherein the -(C1-C6) alkyl group is a tert -butyl group or an iso-propyl group. 
Spoj prema zahtjevu 37, naznačen time da -(C1-C6) alkilna skupina je tert-butilna skupina ili izo-propilna skupina.
The compound of claim 18, wherein the -(C1-C6) alkyl group is a tert -butyl group or an iso-propyl group. 
Spoj prema zahtjevu 18, naznačen time da -(C1-C6) alkilna skupina je tert-butilna skupina ili iso-propilna skupina.
A composition comprising an effective amount of the compound of claim 1 or claim 20 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient. 
Pripravak naznačen time da sadrži učinkovitu količinu spoja prema zahtjevu 1 ili zahtjevu 20 ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljiv nosač ili pomoćnu tvar.
Use of an effective amount of a compound of claim 1 or claim 10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating pain, urinary incontinence, an ulcer, irritable-bowel syndrome or inflammatory-bowel disease. 
Farmaceutski pripravak naznačen time da sadrži učinkovitu količinu spoja prema zahtjevu 1 ili zahtjevu 20 ili njegovu farmaceutski prihvatljivu sol za uporabu kod liječenja boli, urinarne inkontinencije, čira, sindroma iritabilnog crijeva ili upalnog poremećaja crijeva.
A method for inhibiting VR1 function in a cell in vitro comprising contacting a cell, capable of expressing VR1, with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1 or claim 20. 
Postupak za inhibiranje VR1 funkcije u stanici in vitro naznačen time da sadrži kontaktiranje stanice, koja može izražavati VR1, sa učinkovitom količinom spoja ili farmaceutski prihvatljive soli spoja prema zahtjevu 1 ili zahtjevu 20.
A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1 or claim 20. 
Pribor naznačen time da sadrži spremnik koji sadrži učinkovitu količinu spoja ili farmaceutski prihvatljive soli spoja prema zahtjevu 1 ili zahtjevu 20.
A composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) the compound cyprodinil. 
Pripravak pogodan za kontrolu bolesti uzrokovanih fitopatogenima koji se sastoji od: spoja formule (I) [image] naznačen time da R1 je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; i
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) cyprodinil. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) cyprodinil. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, propiconazole, cyproconazole and epoxiconazole. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, ipconazole, prothioconazole, tebuconazole, epoxiconazole, propiconazole, and cyproconazole. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
A composition suitable for control of diseases caused by phytopathogens comprising a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) the compound fenpropimorph. 
Pripravak koja je pogodan za kontrolu bolesti koje uzrokuju fitopatogeni, naznačen time što sadrži (A) spoj formule (I) [image] pri čemu je R1 difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; te
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fenpropimorf.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fenpropimorf.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) ciprodinil.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) ciprodinil.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropidin. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropidin. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fenpropimorf.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fenpropimorf.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbomene-5-yl)amide and component (B) is selected from azoxystrobin and picoxystrobin. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and component (B) is selected from azoxystrobin and picoxystrobin. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fludioxonil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fenpropimorf.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fludioxonil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fenpropimorf.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fenpropimorf.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fenpropimorf.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fenpropimorf.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fenpropimorf.
A compound of formula I, or a salt thereof, for use in the treatment of a disease or condition comprising inhibiting an immune response, wherein formula I is: wherein n is I; 
Spoj formule I, ili njegova sol, namijenjen upotrebi u liječenju bolesti ili stanja koje se sastoji u inhibiranju imunosnog odgovora, gdje formula I je:
The compound of formula I, or a salt thereof, for use according to claim 1, wherein inhibiting an immune response comprises inhibiting the activation of T-cells. 
Spoj formule I, ili njegova sol, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što inhibiranje imunosnog odgovora se sastoji u inhibiranju aktiviranja T-stanica.
The compound of formula I, or a salt thereof, for use according to claim 1, wherein inhibiting an immune response comprises inhibiting the activation of monocytes. 
Spoj formule I, ili njegova sol, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što inhibiranje imunosnog odgovora se sastoji u inhibiranju aktiviranja monocita.
A compound of formula I, or a salt thereof, for use in the treatment of a disease or condition comprising inhibiting the production, release or both of a pro-inflammatory cytokine, wherein formula I is: wherein n is 1; is C6 to C14 aryl or C6 to C14 aryloxy; and R2 is methyl. 
Spoj formule I, ili njegova sol, namijenjen upotrebi u liječenju bolesti ili stanja koje se sastoji u inhibiranju proizvodnje, otpuštanje, ili oboje, oproupalnog citokina, gdje formula I je: [image] naznačen time što n je 1; je C6 do C14 aril ili C6 do C14 ariloksi; i
The compound of formula I, or a salt thereof, for use according to claim 9, wherein the cytokine is tumour necrosis factor alpha (TNF-a). 
Spoj formule I, ili njegova sol, namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što citokin je čimbenik tumorske nekroze alfa (TNF-a).
A compound of formula I, or a salt thereof, for use in the treatment of a disease or condition comprising inhibiting inflammation, wherein formula I is: wherein n is 1; 
Spoj formule I, ili njegova sol, namijenjen upotrebi u liječenju bolesti ili stanja koje se sastoji u inhibiranju upale, gdje formula I je: [image] naznačen time što n je 1;
The compound of formula I, or a salt thereof, for use according to claim 15, wherein the inflammatory disease or condition is an inflammatory neurological disease or condition. 
Spoj formule I, ili njegova sol, namijenjen upotrebi u skladu s patentnim zahtjevom 15, naznačen time što upalna bolest ili stanje je upalna neurološka bolest ili stanje.
A compound of formula I, or a salt thereof, for use in the treatment of a disease or condition comprising inhibiting the unwanted proliferation of lymphocytes, wherein formula I is: wherein n is 1; 
Spoj formule I, ili njegova sol, namijenjen upotrebi u liječenju bolesti ili stanja koje se sastoji u inhibiranju neželjene proliferacije limfocita, gdje formula I je: [image] naznačen time što n je 1;
A compound of formula I, or a salt thereof, for use in the treatment of a disease or condition comprising inhibiting the unwanted adhesion of lymphocytes, wherein formula I is: wherein n is 1; 
Spoj formule I, ili njegova sol, namijenjen upotrebi u liječenju bolesti ili stanja koje se sastoji u inhibiranju neželjene adhezije limfocita, gdje formula I je: [image] naznačen time što n je 1;
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, propiconazole, cyproconazole and epoxiconazole. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) ciprodinil.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, ipconazole, prothioconazole, tebuconazole, epoxiconazole, propiconazole, and cyproconazole. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) ciprodinil.
is benzyl, cycloalkyl, arylcycloalkyl, adamantyl, aryl or heterocyclyl, wherein benzyl, cycloalkyl, arylcycloalkyl, aryl and heterocyclyl are optionally substituted with one to three substituents independently selected from alkyl, cycloalkyl, alkoxy, hydroxy, halogen, trifluormethyl, trifluoromethoxy, benzyl, phenyl and phenyl substituted with one to three substituents independently selected from alkyl, alkoxy, hydroxy, cycloalkyl, halogen and trifluoromethyl; 
je benzil, cikloalkil, arilcikloalkil, adamantil, aril ili heterociklil, gdje benzil, cikloalkil, arilcikioalkil, aril i heterociklil su po izboru supstituirani jednim do tri supstituenta neovisno odabranima od alkila, cikloalkila, alkoksi, hidroksi, halogena, trifluormetila, trifluorometoksi, benzila, fenila, a fenil je supstituiran jednim do tri supstituenta neovisno odabranima od alkila, alkoksi, hidroksi, cikloalkila, halogena i trifluorometila;